Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals

January 5, 2012

Mucosta^® ophthalmic suspension UD2% releases on January 5, 2012

Otsuka Pharmaceutical Co., Ltd. (Head Office: Chiyoda-ku, Tokyo, Japan; President: Taro Iwamoto) today announced the launch of Mucosta ophthalmic suspension UD 2% for patients with dry eye diagnosed on January 5, 2012 in Japan.

Latest Pharmaceutical Business related News Releases

17 APR 2023

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on brexpiprazole for the Treatment of Agitation Associated with Alzheimer's Dementia

30 JAN 2023

Otsuka Applies for the Additional Indication of Adjunctive Treatmentof Major Depressive Disorder for Rexulti^® (brexpiprazole) in Japan

10 JAN 2023

Otsuka and Schrödinger Announce Single-Target, Drug Discovery Collaboration in Neurology

Most Recent Releases

Otsuka Pharmaceutical Co., Ltd.

Mucosta® ophthalmic suspension UD2% releases on January 5, 2012

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on brexpiprazole for the Treatment of Agitation Associated with Alzheimer's Dementia

Otsuka Applies for the Additional Indication of Adjunctive Treatmentof Major Depressive Disorder for Rexulti® (brexpiprazole) in Japan

Otsuka and Schrödinger Announce Single-Target, Drug Discovery Collaboration in Neurology

Mucosta^® ophthalmic suspension UD2% releases on January 5, 2012

Otsuka Applies for the Additional Indication of Adjunctive Treatmentof Major Depressive Disorder for Rexulti^® (brexpiprazole) in Japan